vincristine

(redirected from Oncovin)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Oncovin: procarbazine, prednisone, vincristine

vincristine

[vin′kri‚stēn]
(pharmacology)
C46H56O10N4 An alkaloid extracted from the periwinkle plant (Vinca rosea) and used, as the sulfate salt, as an antineoplastic drug. Also known as leurocristine.
References in periodicals archive ?
She had received a diagnosis of grade I follicular lymphoma 3 years earlier, and it had been treated with 6 cycles of R-CHOP (rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone).
2 mg per kg of body weight per day for 5 days, given on days 3-7 of chemotherapy) significantly reduced the proportion of patients with non-Hodgkin's lymphoma being treated with cyclophosphamide, doxorubicin, Oncovin, and prednisone who developed an infection after chemotherapy (20% vs.
MOPP - mechlorethamine + oncovin (vincristine) + procarbazine + prednisone
The patient received 2 cycles of cyclophosphamide, Adriamycin (hydroxydoxorubicin), Oncovin (vincristine), and prednisone-rituximab (R-CHOP) with no response.
Fourteen patients were evaluated for response and safety and all had relapsed or refractory HL after initial therapy with the chemotherapy regimens ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) or BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, Oncovin, procarbazine hydrochloride, prednisone) or a combination of chemotherapy with or without consolidative radiation treatment.
4,7,8,10) Consensus guidelines recommend that these lymphomas be treated similarly to a systemic diffuse large B-cell lymphoma with an anthracycline-containing chemotherapeutic regimen, such as rituximab, cyclophosphamide, doxorubicin (adriamycin), oncovin (vincristine), and prednisone (R-CHOP), and possibly including involved field radiation therapy.
Cyclophosphamide, Adriamycin, Oncovin, and prednisone (CHOP) and CHOP-like chemotherapy have achieved positive objective responses; however, anthracycline-based chemotherapy has been associated with superior remission and overall survival rates.
R-EPOCH: rituximab plus etoposide (Bristol-Myers Squibb's Etopophos/Vepesid, Pfizer/Nippon Kayaku's Lastet, Baxter's Celltop, generics), prednisone (Sanofi's Cortancyl, Merck KGaA's Decortin, generics), vincristine (Genus Pharmaceuticals/Nippon Kayaku's Oncovin, generics), cyclophosphamide (Bristol-Myers Squibb's Cytoxan, Pfizer's Cyclophospham, generics) and doxorubicin (Pfizer's Adriamycin/Adriblastine/Adriacin, generics).